|
JPH0637520B2
(ja)
|
1985-07-03 |
1994-05-18 |
味の素株式会社 |
ポリペプチド
|
|
US4973577A
(en)
|
1986-04-04 |
1990-11-27 |
The Salk Institute For Biological Studies |
FSH-releasing peptides
|
|
US5080891A
(en)
|
1987-08-03 |
1992-01-14 |
Ddi Pharmaceuticals, Inc. |
Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
|
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
|
US5096815A
(en)
|
1989-01-06 |
1992-03-17 |
Protein Engineering Corporation |
Generation and selection of novel dna-binding proteins and polypeptides
|
|
US5198346A
(en)
|
1989-01-06 |
1993-03-30 |
Protein Engineering Corp. |
Generation and selection of novel DNA-binding proteins and polypeptides
|
|
WO1992004913A1
(en)
|
1990-09-13 |
1992-04-02 |
Children's Hospital Medical Center Of Northern California |
Method for increasing red blood cell production by treatment with activin or activin-related peptides
|
|
US5118667A
(en)
|
1991-05-03 |
1992-06-02 |
Celtrix Pharmaceuticals, Inc. |
Bone growth factors and inhibitors of bone resorption for promoting bone formation
|
|
US6162896A
(en)
|
1991-05-10 |
2000-12-19 |
The Salk Institute For Biological Studies |
Recombinant vertebrate activin receptors
|
|
US5885794A
(en)
|
1991-05-10 |
1999-03-23 |
The Salk Institute For Biological Studies |
Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily
|
|
US20050186593A1
(en)
|
1991-05-10 |
2005-08-25 |
The Salk Institute For Biological Studies |
Cloning and recombinant production of CRF receptor(s)
|
|
JPH06500574A
(ja)
|
1991-05-10 |
1994-01-20 |
ザ ソーク インスティテュート フォア バイオロジカル スタディーズ |
アクチビン／ＴＧＦ―βスーパーファミリーのレセプターのクローニングおよび組換えによる産生
|
|
US6287816B1
(en)
|
1991-06-25 |
2001-09-11 |
Genetics Institute, Inc. |
BMP-9 compositions
|
|
ATE175441T1
(de)
|
1991-06-25 |
1999-01-15 |
Genetics Inst |
Bmp-9 zusammensetzungen
|
|
US6692925B1
(en)
|
1992-11-17 |
2004-02-17 |
Ludwig Institute For Cancer Research |
Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use
|
|
EP1475440A3
(en)
|
1993-01-12 |
2004-11-17 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor-3
|
|
US5637480A
(en)
|
1993-05-12 |
1997-06-10 |
Genetics Institute, Inc. |
DNA molecules encoding bone morphogenetic protein-10
|
|
AU677849B2
(en)
|
1993-05-12 |
1997-05-08 |
Genetics Institute, Llc |
BMP-10 compositions
|
|
US5677196A
(en)
|
1993-05-18 |
1997-10-14 |
University Of Utah Research Foundation |
Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
|
|
US5831050A
(en)
|
1993-06-07 |
1998-11-03 |
Creative Biomolecules, Inc. |
Morphogen cell surface receptor
|
|
ATE355369T1
(de)
|
1993-10-14 |
2006-03-15 |
Harvard College |
Verfahren zur induzierung und zur erhaltung neuronalen zellen
|
|
US5525490A
(en)
|
1994-03-29 |
1996-06-11 |
Onyx Pharmaceuticals, Inc. |
Reverse two-hybrid method
|
|
US5658876A
(en)
|
1994-04-28 |
1997-08-19 |
The General Hospital Corporation |
Activin antagonists as novel contraceptives
|
|
US5760010A
(en)
|
1995-01-01 |
1998-06-02 |
Klein; Ira |
Method of treating liver disorders with a macrolide antibiotic
|
|
US5814565A
(en)
|
1995-02-23 |
1998-09-29 |
University Of Utah Research Foundation |
Integrated optic waveguide immunosensor
|
|
ATE352638T1
(de)
|
1995-04-11 |
2007-02-15 |
Gen Hospital Corp |
REVERSE ßTWO-HYBRIDß-SYSTEME
|
|
EP0771873A3
(en)
|
1995-10-27 |
1998-03-04 |
Takeda Chemical Industries, Ltd. |
Neuronal cell-specific receptor protein
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
US6004780A
(en)
|
1996-03-26 |
1999-12-21 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
|
US20050244867A1
(en)
|
1996-03-26 |
2005-11-03 |
Human Genome Sciences, Inc. |
Growth factor HTTER36
|
|
EP0939816A1
(en)
|
1996-10-25 |
1999-09-08 |
G.D. SEARLE & CO. |
Circularly permuted erythropoietin receptor agonists
|
|
US6605699B1
(en)
|
1997-01-21 |
2003-08-12 |
Human Genome Sciences, Inc. |
Galectin-11 polypeptides
|
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
|
US6656475B1
(en)
|
1997-08-01 |
2003-12-02 |
The Johns Hopkins University School Of Medicine |
Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
|
|
AU8666398A
(en)
|
1997-08-01 |
1999-02-22 |
Johns Hopkins University School Of Medicine, The |
Methods to identify growth differentiation factor (gdf) receptors
|
|
US6696260B1
(en)
|
1997-08-01 |
2004-02-24 |
The Johns Hopkins University School Of Medicine |
Methods to identify growth differentiation factor (GDF) binding proteins
|
|
US6891082B2
(en)
|
1997-08-01 |
2005-05-10 |
The Johns Hopkins University School Of Medicine |
Transgenic non-human animals expressing a truncated activintype II receptor
|
|
US6953662B2
(en)
|
1997-08-29 |
2005-10-11 |
Human Genome Sciences, Inc. |
Follistatin-3
|
|
EP1015468A4
(en)
|
1997-08-29 |
2000-09-06 |
Human Genome Sciences Inc |
FOLLISTATINE-3
|
|
US6696411B1
(en)
|
1998-04-22 |
2004-02-24 |
Cornell Research Foundation, Inc. |
Canine erythropoietin gene and recombinant protein
|
|
CA2343268A1
(en)
|
1998-09-17 |
2000-03-23 |
Eli Lilly And Company |
Protein formulations
|
|
AU5502799A
(en)
|
1998-09-22 |
2000-04-10 |
Long Yu |
New human growth differentiation factor encoding sequence and polypeptide encoded by such dna sequence and producing method thereof
|
|
US6472179B2
(en)
|
1998-09-25 |
2002-10-29 |
Regeneron Pharmaceuticals, Inc. |
Receptor based antagonists and methods of making and using
|
|
US6548634B1
(en)
|
1998-09-30 |
2003-04-15 |
Chiron Corporation |
Synthetic peptides having FGF receptor affinity
|
|
US6777205B1
(en)
|
1998-11-06 |
2004-08-17 |
Sterrenbeld Biotechnologie North America, Inc. |
Host cells expressing recombinant human erythropoietin
|
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
|
ATE322681T1
(de)
|
1999-01-21 |
2006-04-15 |
Metamorphix Inc |
Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
|
|
CA2365449A1
(en)
|
1999-04-19 |
2000-10-26 |
Kyowa Hakko Kogyo Co., Ltd. |
Inhibitor of the growth of androgen-independent tumor
|
|
US6468543B1
(en)
|
1999-05-03 |
2002-10-22 |
Zymogenetics, Inc. |
Methods for promoting growth of bone using ZVEGF4
|
|
US6746847B1
(en)
|
1999-07-04 |
2004-06-08 |
Vitak |
Diagnostic assay for human matrix Gla-protein and its use as a biomarker
|
|
KR20020065517A
(ko)
|
1999-11-12 |
2002-08-13 |
맥시겐 홀딩스 리미티드 |
인터페론 감마 접합체
|
|
NZ519546A
(en)
|
1999-12-15 |
2005-07-29 |
Res Dev Foundation |
Betaglycan as an inhibin receptor and uses thereof
|
|
JP4487376B2
(ja)
|
2000-03-31 |
2010-06-23 |
味の素株式会社 |
腎疾患治療剤
|
|
US6627424B1
(en)
|
2000-05-26 |
2003-09-30 |
Mj Bioworks, Inc. |
Nucleic acid modifying enzymes
|
|
AU2001269709A1
(en)
|
2000-07-19 |
2002-02-05 |
Eli Lilly And Company |
Nucleic acids, vectors, host cells, polypeptides, and uses thereof
|
|
US6632180B1
(en)
|
2000-09-07 |
2003-10-14 |
John H. Laragh |
Method for evaluating and treating hypertension
|
|
DE10045591A1
(de)
|
2000-09-15 |
2002-04-04 |
Klaus Pfizenmaier |
Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
|
|
EP1356075A4
(en)
|
2000-10-16 |
2005-04-13 |
Compound Therapeutics Inc |
PROTEIN EQUIPMENT FOR ANTIBODY MIMETICS AND OTHER TIE PROTEINS
|
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
|
AU2567002A
(en)
|
2000-11-20 |
2002-05-27 |
Univ Illinois |
Membrane scaffold proteins
|
|
AU2002236558A1
(en)
|
2000-12-01 |
2002-06-11 |
Regents Of The University Of California |
Method and composition for modulating bone growth
|
|
US20030082233A1
(en)
|
2000-12-01 |
2003-05-01 |
Lyons Karen M. |
Method and composition for modulating bone growth
|
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
TW200526779A
(en)
|
2001-02-08 |
2005-08-16 |
Wyeth Corp |
Modified and stabilized GDF propeptides and uses thereof
|
|
US20040132675A1
(en)
|
2002-02-08 |
2004-07-08 |
Calvin Kuo |
Method for treating cancer and increasing hematocrit levels
|
|
US7294472B2
(en)
|
2001-03-14 |
2007-11-13 |
Caden Biosciences |
Method for identifying modulators of G protein coupled receptor signaling
|
|
EP1369130A1
(en)
|
2001-03-16 |
2003-12-10 |
Takeda Chemical Industries, Ltd. |
Process for producing sustained release preparation
|
|
US20030082630A1
(en)
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
|
PL403488A1
(pl)
|
2001-05-24 |
2013-07-08 |
Zymogenetics, Inc. |
Zastosowanie bialka fuzyjnego TACI-immunoglobulina, bialko fuzyjne, czasteczka kwasu nukleinowego kodujaca bialko fuzyjne, kompozycja farmaceutyczna i sposób wytwarzania bialka fuzyjnego TACI-immunoglobulina
|
|
WO2002094864A2
(en)
|
2001-05-25 |
2002-11-28 |
Genset S.A. |
Human cdnas and proteins and uses thereof
|
|
AUPR638101A0
(en)
|
2001-07-13 |
2001-08-09 |
Bioa Pty Limited |
Composition and method for treatment of disease
|
|
EP1416273B1
(en)
|
2001-07-17 |
2009-11-11 |
Teijin Limited |
Method of selecting substance characterized by assaying ppard activating effect and drug
|
|
US6855344B2
(en)
|
2001-07-17 |
2005-02-15 |
Integrated Chinese Medicine Holdings, Ltd. |
Compositions and methods for prostate and kidney health and disorders, an herbal preparation
|
|
KR100453877B1
(ko)
|
2001-07-26 |
2004-10-20 |
메덱스젠 주식회사 |
연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
|
|
US7320789B2
(en)
|
2001-09-26 |
2008-01-22 |
Wyeth |
Antibody inhibitors of GDF-8 and uses thereof
|
|
US6784154B2
(en)
|
2001-11-01 |
2004-08-31 |
University Of Utah Research Foundation |
Method of use of erythropoietin to treat ischemic acute renal failure
|
|
US20030144203A1
(en)
|
2001-12-19 |
2003-07-31 |
Voyager Pharmaceutical Corporation |
Methods for slowing senescence and treating and preventing diseases associated with senescence
|
|
US6998118B2
(en)
|
2001-12-21 |
2006-02-14 |
The Salk Institute For Biological Studies |
Targeted retrograde gene delivery for neuronal protection
|
|
AU2003216250A1
(en)
|
2002-02-11 |
2003-09-04 |
Genentech, Inc. |
Antibody variants with faster antigen association rates
|
|
WO2003072715A2
(en)
|
2002-02-21 |
2003-09-04 |
Wyeth |
Gasp1: a follistatin domain containing protein
|
|
US20030219846A1
(en)
|
2002-02-28 |
2003-11-27 |
Pfizer Inc. |
Assay for activity of the ActRIIB kinase
|
|
AU2003232485A1
(en)
|
2002-04-18 |
2003-10-27 |
Mtm Laboratories Ag |
Neopeptides and methods useful for detection and treatment of cancer
|
|
KR20050083635A
(ko)
|
2002-08-16 |
2005-08-26 |
와이어쓰 |
Ｂｍｐ-2 에스트로겐 반응 요소 및 이의 사용 방법
|
|
US7261893B2
(en)
|
2002-10-22 |
2007-08-28 |
Wyeth |
Neutralizing antibodies against GDF-8 and uses therefor
|
|
US20040223966A1
(en)
|
2002-10-25 |
2004-11-11 |
Wolfman Neil M. |
ActRIIB fusion polypeptides and uses therefor
|
|
AU2002953327A0
(en)
|
2002-12-12 |
2003-01-09 |
Monash University |
Methods of diagnosing prognosing and treating activin associated diseases and conditions
|
|
NZ541593A
(en)
|
2003-02-07 |
2009-05-31 |
Prometic Biosciences Inc |
Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
|
|
US20040197828A1
(en)
|
2003-03-26 |
2004-10-07 |
Gaddy Dana P. |
Method for diagnosis and treatment of bone turnover
|
|
WO2010019832A2
(en)
|
2008-08-13 |
2010-02-18 |
Designer Molecules, Inc. |
Amide-extended crosslinking compounds and methods for use thereof
|
|
US20070184052A1
(en)
|
2003-05-09 |
2007-08-09 |
Lin Herbert Y |
Soluble tgf-b type III receptor fusion proteins
|
|
KR20060026860A
(ko)
|
2003-06-02 |
2006-03-24 |
와이어쓰 |
신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
|
|
CA2529623A1
(en)
|
2003-06-16 |
2005-02-17 |
Celltech R & D, Inc. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
|
US7611465B2
(en)
|
2003-07-15 |
2009-11-03 |
Board Of Regents, The University Of Texas System |
Rapid and accurate detection of bone quality using ultrasound critical angle reflectometry
|
|
WO2005009460A2
(en)
|
2003-07-25 |
2005-02-03 |
Medexis, S.A. |
Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer
|
|
DE10335211A1
(de)
|
2003-08-01 |
2005-02-17 |
Robert Bosch Gmbh |
Kraftstoff-Einspritzvorrichtung für eine Brennkraftmaschine
|
|
US20070135336A1
(en)
|
2003-09-15 |
2007-06-14 |
De Kretser David |
Follistatin isoforms and uses thereof
|
|
US8895540B2
(en)
|
2003-11-26 |
2014-11-25 |
DePuy Synthes Products, LLC |
Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
|
|
JP4987484B2
(ja)
|
2004-01-22 |
2012-07-25 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
補体結合が低下した抗癌抗体
|
|
US20050197292A1
(en)
|
2004-01-30 |
2005-09-08 |
Glennda Smithson |
Compositions and methods for treating T-cell mediated pathological conditions
|
|
CA2561317A1
(en)
|
2004-03-26 |
2005-10-13 |
Acceleron Pharma Inc. |
Bmp-3 propeptides and related methods
|
|
US7459527B2
(en)
|
2004-03-31 |
2008-12-02 |
Xencor, Inc. |
BMP-7 variants with improved properties
|
|
US7741284B2
(en)
|
2004-05-12 |
2010-06-22 |
Acceleron Pharma Inc. |
BMP10 propeptides and related methods
|
|
EP1771557B1
(en)
|
2004-06-24 |
2014-12-31 |
Acceleron Pharma Inc. |
GDF3 Propeptides and Related Methods
|
|
EP1771470B1
(en)
|
2004-07-23 |
2013-06-26 |
Acceleron Pharma Inc. |
Actrii receptor polypeptides, methods and compositions
|
|
WO2006020884A2
(en)
|
2004-08-12 |
2006-02-23 |
Wyeth |
Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors
|
|
US8435948B2
(en)
|
2004-09-29 |
2013-05-07 |
Mount Sinai School Of Medicine Of New York University |
Methods for inhibiting osteoclastic bone resorption and bone loss comprising administration of an anti-FSH or anti-FSHR antibody
|
|
US20060234299A1
(en)
|
2004-11-16 |
2006-10-19 |
Avidia Research Institute |
Protein scaffolds and uses thereof
|
|
NZ538097A
(en)
|
2005-02-07 |
2006-07-28 |
Ovita Ltd |
Method and compositions for improving wound healing
|
|
CA2597925A1
(en)
|
2005-02-16 |
2006-08-24 |
The General Hospital Corporation |
Use of a human hemojuvelin product to regulate hepcidin-mediated iron metabolism
|
|
KR20080003929A
(ko)
|
2005-04-26 |
2008-01-08 |
아지노모토 가부시키가이샤 |
골수 적혈구 전구 세포 분화 촉진제
|
|
JP2007099764A
(ja)
|
2005-09-09 |
2007-04-19 |
Ajinomoto Co Inc |
血糖低下剤
|
|
PT1931697E
(pt)
|
2005-09-28 |
2010-12-06 |
Zymogenetics Inc |
Antagonistas de il-17a e il-17f e processos para a sua utilização
|
|
AU2006304778B2
(en)
|
2005-10-21 |
2011-04-28 |
Amgen Inc. |
Methods of decreasing vascular calcification using IL-1 inhibitors
|
|
US8067562B2
(en)
|
2005-11-01 |
2011-11-29 |
Amgen Inc. |
Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
RS58231B1
(sr)
|
2005-11-23 |
2019-03-29 |
Acceleron Pharma Inc |
Antagonisti aktivin-actriia i primene za stimulaciju rasta kostiju
|
|
CA2856436A1
(en)
|
2005-12-06 |
2007-06-14 |
Amgen Inc. |
Uses of myostatin antagonists
|
|
JP2009519984A
(ja)
|
2005-12-20 |
2009-05-21 |
メルク フロスト カナダ リミテツド |
ステアロイル−補酵素δ−９デサチュラーゼ阻害剤としての芳香族複素環化合物
|
|
CA2634940A1
(en)
|
2005-12-21 |
2007-07-05 |
Schering Corporation |
Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
|
|
WO2007076127A2
(en)
|
2005-12-22 |
2007-07-05 |
Biogen Idec Ma Inc |
Condensed imidazoles or pyrazoles and their use as transforming growth factor modulators
|
|
JP4925364B2
(ja)
|
2006-01-20 |
2012-04-25 |
ベックマン コールター， インコーポレイテッド |
鉄欠乏を検出する方法
|
|
US7820721B2
(en)
|
2006-01-25 |
2010-10-26 |
Wellstat Therapeutics Corporation |
Compounds for the treatment of metabolic disorders
|
|
CN101394738A
(zh)
|
2006-02-28 |
2009-03-25 |
维尔斯达医疗公司 |
用于治疗代谢紊乱的化合物
|
|
US8008074B2
(en)
|
2006-03-20 |
2011-08-30 |
The Uab Research Foundation |
Compositions and methods for improving bone mass through modulation of receptors of PTH and fragments thereof
|
|
EP2007813A2
(en)
|
2006-04-14 |
2008-12-31 |
Amgen Inc. |
Agonist erythropoietin receptor antibodies
|
|
WO2007133653A2
(en)
|
2006-05-09 |
2007-11-22 |
Hemaquest Pharmaceuticals, Inc. |
Methods for treating blood disorders
|
|
NZ574331A
(en)
|
2006-07-21 |
2011-01-28 |
Lyne Lab |
Liquid compositions of calcium acetate
|
|
GB0615129D0
(en)
|
2006-07-29 |
2006-09-06 |
Univ Cardiff |
Anti-cancer activity of BMP-9 and BMP-10 and their use in cancer therapies
|
|
WO2008030367A2
(en)
|
2006-09-01 |
2008-03-13 |
The General Hospital Corporation |
Selective myostatin inhibitors
|
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
WO2008060139A1
(en)
|
2006-11-17 |
2008-05-22 |
Erasmus University Medical Center Rotterdam |
Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein
|
|
US20100003190A1
(en)
|
2006-12-08 |
2010-01-07 |
Caritas St. Elizabeth's Medical Center Of Boston, Inc. |
Method for protecting renal tubular epithelial cells from radiocontrast nephropathy (RCN)
|
|
WO2008072723A1
(ja)
|
2006-12-14 |
2008-06-19 |
Forerunner Pharma Research Co., Ltd. |
抗Claudin3モノクローナル抗体およびそれを用いる癌の治療および診断
|
|
US8895016B2
(en)
*
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
MX2009006651A
(es)
|
2006-12-18 |
2009-08-26 |
Acceleron Pharma Inc |
Antagonistas de activina-actrii y usos para incrementar los niveles de globulos rojo.
|
|
US20100028332A1
(en)
|
2006-12-18 |
2010-02-04 |
Acceleron Pharma Inc. |
Antagonists of actriib and uses for increasing red blood cell levels
|
|
KR101526613B1
(ko)
|
2007-02-01 |
2015-06-26 |
악셀레론 파마 인코포레이티드 |
액티빈-ａｃｔｒⅱａ 길항제 및 유방암을 치료 또는 예방하기 위한 이들의 용도
|
|
TW201940502A
(zh)
|
2007-02-02 |
2019-10-16 |
美商艾瑟勒朗法瑪公司 |
衍生自ＡｃｔＲＩＩＢ的變體與其用途
|
|
TW201808334A
(zh)
|
2007-02-09 |
2018-03-16 |
艾瑟勒朗法瑪公司 |
包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
|
|
TWI454479B
(zh)
*
|
2007-03-06 |
2014-10-01 |
Amgen Inc |
變異之活動素受體多肽及其用途
|
|
WO2008151078A1
(en)
|
2007-06-01 |
2008-12-11 |
Wyeth |
Methods and compositions for modulating bmp-10 activity
|
|
WO2009009059A1
(en)
|
2007-07-09 |
2009-01-15 |
Biogen Idec Ma Inc. |
Spiro compounds as antagonists of tgf-beta
|
|
JP2010535708A
(ja)
|
2007-08-03 |
2010-11-25 |
ビオマリン アイジーエー リミテッド |
デュシェンヌ型筋ジストロフィーの治療のための薬物併用
|
|
GB0715087D0
(en)
|
2007-08-03 |
2007-09-12 |
Summit Corp Plc |
Drug combinations for the treatment of duchenne muscular dystrophy
|
|
GB0715938D0
(en)
|
2007-08-15 |
2007-09-26 |
Vastox Plc |
Method of treatment of duchenne muscular dystrophy
|
|
WO2009025651A1
(en)
|
2007-08-17 |
2009-02-26 |
University Of Maine System Board Of Trustees |
Biologically active peptide and method of using the same
|
|
EP2207562B1
(en)
|
2007-09-18 |
2017-05-31 |
Acceleron Pharma, Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
|
PE20091163A1
(es)
|
2007-11-01 |
2009-08-09 |
Wyeth Corp |
Anticuerpos para gdf8
|
|
JP5583591B2
(ja)
|
2007-11-21 |
2014-09-03 |
アムジエン・インコーポレーテツド |
Ｗｉｓｅ結合抗体及びエピトープ
|
|
EP2265603B1
(en)
|
2008-03-13 |
2014-05-07 |
The General Hospital Corporation |
Inhibitors of the bmp signaling pathway
|
|
EP2283119B1
(en)
|
2008-05-06 |
2015-01-07 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
|
WO2009137075A1
(en)
|
2008-05-06 |
2009-11-12 |
Acceleron Pharma Inc. |
Anti-activin antibodies and uses for promoting bone growth
|
|
EP3415161A1
(en)
|
2008-06-26 |
2018-12-19 |
Acceleron Pharma Inc. |
The use of an actriib antagonist for the treatment of anemia
|
|
WO2009158033A2
(en)
|
2008-06-26 |
2009-12-30 |
Acceleron Pharma Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
HUE063136T2
(hu)
|
2008-08-14 |
2023-12-28 |
Acceleron Pharma Inc |
GDF-Csapdák
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
EA201100832A1
(ru)
*
|
2008-11-26 |
2011-12-30 |
Амген Инк. |
Варианты полипептидов рецептора iib активина и их применение
|
|
CA2749544A1
(en)
|
2009-01-13 |
2010-07-22 |
Acceleron Pharma Inc. |
Methods for increasing adiponectin
|
|
CN102307598A
(zh)
|
2009-02-05 |
2012-01-04 |
迪格纳生物技术公司 |
TGF-β1抑制肽的药物制剂
|
|
EA027071B1
(ru)
|
2009-04-27 |
2017-06-30 |
Новартис Аг |
АНТИТЕЛО К ActRIIB И СОДЕРЖАЩАЯ ЕГО КОМПОЗИЦИЯ
|
|
KR20120049214A
(ko)
|
2009-06-08 |
2012-05-16 |
악셀레론 파마 인코포레이티드 |
발열성 지방세포를 증가시키는 방법
|
|
US8293881B2
(en)
|
2009-06-12 |
2012-10-23 |
Acceleron Pharma Inc. |
Isolated nucleic acid encoding a truncated ActRIIB fusion protein
|
|
KR102170682B1
(ko)
|
2009-08-13 |
2020-10-28 |
악셀레론 파마 인코포레이티드 |
적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용
|
|
BR112012005225B8
(pt)
|
2009-09-09 |
2023-01-10 |
Acceleron Pharma Inc |
Uso de uma proteína de fusão actriib-fc para o tratamento de um transtorno relacionado ao osso ou associado à perda de músculo por crescimento muscular insuficiente
|
|
EP2496247B1
(en)
|
2009-11-03 |
2017-08-23 |
Acceleron Pharma, Inc. |
Methods for treating fatty liver disease
|
|
WO2011063018A1
(en)
|
2009-11-17 |
2011-05-26 |
Acceleron Pharma Inc. |
Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
|
|
RU2421126C1
(ru)
|
2010-01-25 |
2011-06-20 |
ФГУ ВПО Кубанский государственный медицинский университет Росздрава (КГМУ) |
Способ прогнозирования эффективности планируемой стандартной терапии острого нефрита
|
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
|
KR20220075438A
(ko)
|
2011-10-17 |
2022-06-08 |
악셀레론 파마 인코포레이티드 |
비효율적 적혈구생성 치료를 위한 방법 및 조성물
|
|
EP2868667B1
(en)
|
2012-07-02 |
2019-01-30 |
Kyowa Hakko Kirin Co., Ltd. |
Therapeutic agent for anemia including renal anemia and cancer-induced anemia which contains anti-bmp9 antibody as active ingredient
|
|
AU2013334660B2
(en)
|
2012-10-24 |
2018-08-09 |
Celgene Corporation |
Methods for treating anemia
|
|
WO2014066486A2
(en)
|
2012-10-24 |
2014-05-01 |
Celgene Corporation |
Biomarker for use in treating anemia
|
|
MX366336B
(es)
|
2012-11-02 |
2019-07-05 |
Celgene Corp |
Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros.
|
|
JP6649895B2
(ja)
|
2014-04-18 |
2020-02-19 |
アクセルロン ファーマ， インコーポレイテッド |
赤血球レベルを増加させ、そして鎌状赤血球症を処置するための方法
|
|
TN2016000553A1
(en)
|
2014-06-13 |
2018-04-04 |
Acceleron Pharma Inc |
Methods and compositions for treating ulcers
|
|
MA41052A
(fr)
|
2014-10-09 |
2017-08-15 |
Celgene Corp |
Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
|
|
IL252631B2
(en)
|
2014-12-03 |
2024-06-01 |
Celgene Corp |
ACTIVIN-ACTRII antagonists and uses for the treatment of anemia
|
|
MA41119A
(fr)
|
2014-12-03 |
2017-10-10 |
Acceleron Pharma Inc |
Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique
|
|
KR101759725B1
(ko)
*
|
2015-04-27 |
2017-08-01 |
동우당제약(주) |
지골피추출물로부터 분리된 디하이드로파세익 애시드 쓰리프라임-오-베타-디-글루코피라노사이드를 포함하는 골다공증 예방 및 치료용 조성물
|
|
JOP20160092B1
(ar)
|
2015-05-13 |
2023-03-28 |
Celgene Corp |
علاج البيتا ثلاسيميا باستخدام مصطبة لجائنية
|
|
EP3298034A4
(en)
|
2015-05-20 |
2019-02-13 |
Celgene Corporation |
IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS
|
|
US11123430B2
(en)
|
2015-11-04 |
2021-09-21 |
Acceleron Pharma Inc. |
Methods for increasing red blood cell levels and treating ineffective erythropoiesis
|
|
CN108697793B
(zh)
|
2015-11-23 |
2023-08-01 |
阿塞勒隆制药公司 |
治疗眼睛疾病的方法
|
|
US10889882B2
(en)
|
2016-05-27 |
2021-01-12 |
Novelis Inc. |
High strength and corrosion resistant alloy for use in HVAC and R systems
|
|
RS62011B1
(sr)
|
2016-07-15 |
2021-07-30 |
Acceleron Pharma Inc |
Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije
|
|
HUE067225T2
(hu)
|
2016-07-27 |
2024-10-28 |
Acceleron Pharma Inc |
Mielofibrózis kezelésére szolgáló készítmények
|
|
CA3039525A1
(en)
|
2016-10-05 |
2018-04-12 |
Acceleron Pharma Inc. |
Variant actriib proteins and uses thereof
|
|
HUE068733T2
(hu)
|
2017-06-14 |
2025-01-28 |
Celgene Corp |
Eljárások mieloproliferatív neoplazma-asszociált mielofibrózis anémia kezelésére
|
|
US20210346464A1
(en)
|
2018-10-31 |
2021-11-11 |
Celgene Corporation |
TREATMENT OF ANEMIA DUE TO VERY LOW, LOW, OR INTERMEDIATE RISK MYELODYSPLASTIC SYNDROMES IN SUBJECTS WITH RING SIDEROBLASTS USING ACTIVIN-ACTRll LIGAND TRAPS
|
|
JP2023523568A
(ja)
|
2020-04-13 |
2023-06-06 |
セルジーン コーポレーション |
ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法
|
|
CA3177632A1
(en)
|
2020-05-15 |
2021-11-18 |
Melih ACAR |
Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors
|